Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 17/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 17/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 14/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL650663 | 0.82 | MAPT (0.45) | HDAC1HDAC2HDAC3 | |
| SCHEMBL653107 | 0.79 | KCNH2 (0.49) | KCNH2HDAC1 | |
| SCHEMBL651416 | 0.79 | HDAC1 (0.58) | KCNH2HDAC1HDAC2HDAC3 | |
| SCHEMBL1931248 | 0.74 | HDAC1 (0.55) | HDAC1HDAC2HDAC3 | |
| SCHEMBL1512084 | 0.73 | KEAP1 (0.42) | HDAC1HDAC2HDAC3 | |
| SCHEMBL21857924 | 0.73 | KCNH2 (0.62) | KCNH2HDAC1HDAC2HDAC3 | |
| SCHEMBL2212580 | 0.73 | HDAC1 (0.54) | HDAC1HDAC2HDAC3 | |
| SCHEMBL1931687 | 0.72 | HDAC1 (0.53) | HDAC1HDAC2HDAC3 | |
| SCHEMBL247809 | 0.72 | KDM4E (0.38) | HDAC1HDAC2HDAC3 | |
| SCHEMBL17507930 | 0.71 | ALDH1A1 (0.51) | HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210332036-A1 | PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2021-10-28 | — | — | US | disclosed |
| EP-3725787-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | Regenacy Pharmaceuticals, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20170240535-A1 | HDAC1/2 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR COGNITIVE DISORDERS | REGENACY PHARMACEUTICALS, LLC | 2017-08-24 | — | — | US | disclosed |
| WO-2017136451-A1 | HDAC1/2 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR COGNITIVE DISORDERS | REGENACY PHARMACEUTICALS, LLC (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20160137630-A1 | INDUCTION OF GATA2 BY HDAC1 AND HDAC2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2016-05-19 | — | — | US | disclosed |
| US-8349825-B2 | Spirocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8119819-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-02-21 | — | — | US | disclosed |
| US-8119685-B2 | Disubstituted aniline compounds | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119652-B2 | Aryl-fused spirocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-7981874-B2 | Phosphorus derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | disclosed |
| US-20090239849-A1 | Aryl-Fused Spirocyclic Compounds | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-7524969-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-28 | — | — | US | disclosed |
| EP-2049124-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009020589-A1 | SILICON DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008010985-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20040082576-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1411929-A2 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003090869-A1 | LXR MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-06 | — | — | WO | disclosed |
| WO-2002058698-A2 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137630-A1 | INDUCTION OF GATA2 BY HDAC1 AND HDAC2 INHIBITORS | GATAD2B, GATAD2A, HDAC2 | KCNH2 3364/4885HDAC1 4/4885HDAC2 3/4885 |
| US-20210332036-A1 | PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | KCNH2 3888/4885HDAC1 1/4885HDAC2 2/4885 |
| US-20090239849-A1 | Aryl-Fused Spirocyclic Compounds | HDAC1, BRDT, HDAC5 | KCNH2 2306/4885HDAC1 1/4885HDAC2 6/4885 |
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC5, PPM1A, PTEN | KCNH2 2991/4885HDAC1 4/4885HDAC2 8/4885 |
| US-20040082576-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | MLYCD, ME3, ACACA | KCNH2 4004/4885HDAC1 228/4885HDAC2 623/4885 |
| US-20170240535-A1 | HDAC1/2 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR COGNITIVE DISORDERS | HDAC1, HDAC2, HDAC11 | KCNH2 4701/4885HDAC1 1/4885HDAC2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.